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Summary
Background People with severe mental illnesses such as schizophrenia are three times more likely to smoke than the 
wider population, contributing to widening health inequalities. Smoking remains the largest modiiable risk factor 
for this health inequality, but people with severe mental illness have not historically engaged with smoking cessation 
services. We aimed to test the efectiveness of a combined behavioural and pharmacological smoking cessation 
intervention targeted speciically at people with severe mental illness.
Methods In the smoking cessation intervention for severe mental illness (SCIMITAR+) trial, a pragmatic, randomised 
controlled study, we recruited heavy smokers with bipolar disorder or schizophrenia from 16 primary care and 
21 community-based mental health sites in the UK. Participants were eligible if they were aged 18 years or older, and 
smoked at least ive cigarettes per day. Exclusion criteria included substantial comorbid drug or alcohol problems 
and people who lacked capacity to consent at the time of recruitment. Using computer-generated random numbers, 
participants were randomly assigned (1:1) to a bespoke smoking cessation intervention or to usual care. Participants, 
mental health specialists, and primary care physicians were unmasked to assignment. The bespoke smoking 
cessation intervention consisted of behavioural support from a mental health smoking cessation practitioner and 
pharmacological aids for smoking cessation, with adaptations for people with severe mental illness—such as, 
extended pre-quit sessions, cut down to quit, and home visits. Access to pharmacotherapy was via primary care after 
discussion with the smoking cessation specialist. Under usual care participants were ofered access to local smoking 
cessation services not speciically designed for people with severe mental illnesses. The primary endpoint was 
smoking cessation at 12 months ascertained via carbon monoxide measurements below 10 parts per million and 
self-reported cessation for the past 7 days. Secondary endpoints were biologically veriied smoking cessation at 
6 months; number of cigarettes smoked per day, Fagerström Test for Nicotine Dependence (FTND) and Motivation 
to Quit (MTQ) questionnaire; general and mental health functioning determined via the Patient Health 
Questionnaire-9 (PHQ-9), the Generalised Anxiety Disorder-7 (GAD-7) questionnaire, and 12-Item Short Form 
Health Survey (SF-12); and body-mass index (BMI). This trial was registerd with the ISRCTN registry, number 
ISRCTN72955454, and is complete.
Findings Between Oct 7, 2015, and Dec 16, 2016, 526 eligible patients were randomly assigned to the bespoke smoking 
cessation intervention (n=265) or usual care (n=261). 309 (59%) participants were male, median age was 47·2 years 
(IQR 36·3–54·5), with high nicotine dependence (mean 24 cigarettes per day [SD 13·2]), and the most common 
severe mental disorders were schizophrenia or other psychotic illness (n=343 [65%]), bipolar disorder (n=115 [22%]), 
and schizoafective disorder (n=66 [13%]). 234 (88%) of intervention participants engaged with the treatment 
programme and attended 6·4 (SD 3·5) quit smoking sessions, with an average duration of 39 min (SD 17; median 
35 min, range 5–120). Veriied quit data at 12 months were available for 219 (84%) of 261 usual care and 223 (84%) of 
265 intervention participants. The proportion of participants who had quit at 12 months was higher in the intervention 
group than in the usual care group, but non-signiicantly (34 [15%] of 223 [13% of those assigned to group] vs 22 [10%] 
of 219 [8% of those assigned to group], risk diference 5·2%, 95% CI –1·0 to 11·4; odds ratio [OR] 1·6, 95% CI 0·9 to 
2·9; p=0·10). The proportion of participants who quit at 6 months was signiicantly higher in the intervention group 
than in the usual care group (32 [14%] of 226  vs 14 [6%] of 217; risk diference 7·7%, 95% CI 2·1 to 13·3; OR 2·4, 
95% CI 1·2 to 4·6; p=0·010). The incidence rate ratio for number of cigarettes smoked per day at 6 months was 0·90 
(95% CI 0·80 to 1·01; p=0·079), and at 12 months was 1·00 (0·89 to 1·13; p=0·95). At both 6 months and 12 months, 
the intervention group was non-signiicantly favoured in the FTND (adjusted mean diference 6 months –0·18, 
95% CI –0·53 to 0·17, p=0·32; and 12 months –0·01, –0·39 to 0·38, p=0·97) and MTQ questionnaire (adjusted mean 
diference 0·58, –0·01 to 1·17, p=0·056; and 12 months 0·64, 0·04 to 1·24, p=0·038). The PHQ-9 showed no 
diference between the groups (adjusted mean diference at 6 months 0·20, 95% CI –0·85 to 1·24 vs 12 months –0·12, 
–1·18 to 0·94). For the SF-12 survey, we saw evidence of improvement in physical health in the intervention group at 
6 months (adjusted mean diference 1·75, 95% CI 0·21 to 3·28), but this diference was not evident at 12 months 
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(0·59, –1·07 to 2·26); and we saw no diference in mental health between the groups at 6 or 12 months (adjusted 
mean diference at 6 months –0·73, 95% CI –2·82 to 1·36, and 12 months –0·41, –2·35 to 1·53). The GAD-7 
questionnaire showed no diference between the groups (adjusted mean diference at 6 months –0·32 95% CI –1·26 
to 0·62 vs 12 months –0·10, –1·05 to 0·86). No diference in BMI was seen between the groups (adjusted mean 
diference 6 months 0·16, 95% CI –0·54 to 0·85; 12 months 0·25, –0·62 to 1·13).
Interpretation This bespoke intervention is a candidate model of smoking cessation for clinicians and policy makers 
to address high prevalence of smoking. The incidence of quitting at 6 months shows that smoking cessation can be 
achieved, but the waning of this efect by 12 months means more efort is needed for sustained quitting.
Funding National Institute for Health Research Health Technology Assessment Programme. 
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Research in context
Evidence before this study
When first designing this study, we did a systematic review of 
key databases (MEDLINE, Embase, CINAHL, PsycINFO, HMIC, 
the Cochrane Controlled Register of Trials, and The Database 
of Abstracts of Reviews of Effects) from database inception to 
Jan 5, 2008, for publications in English of smoking cessation 
studies and independently extracted data. We included 
randomised controlled trials done in any country or care 
setting with adult smokers with severe mental illness. 
We identified ten small-scale trials that highlighted the 
potential effectiveness of nicotine replacement, bupropion, 
and techniques to change behaviour to enable people with 
severe mental illness to quit smoking. Effect sizes were 
broadly in line with estimates of effect for non-severe mental 
illness populations in the ability of smoking cessation 
interventions to help people quit. We also found that 
smoking cessation is unlikely to cause deterioration in the 
mental health of people with severe mental illness. 
We repeated our review, from database inception to 
Sept 1, 2016, combining search terms for severe mental ill 
health, smoking cessation, and randomised controlled trials, 
adapted from terms developed by the Cochrane groups for 
schizophrenia and tobacco addiction (exact terms are listed in 
the appendix). We found few trials of behavioural 
interventions, no placebo-controlled trials of nicotine 
replacement therapy alone, and an absence of research 
showing how smoking cessation services should be organised 
and delivered within existing mental health services. 
Furthermore, although some trials tested the effectiveness of 
pharmacological treatments, they did not test the 
effectiveness of behavioural interventions based on 
evidence-supported techniques to change behaviour.
Added value of this study
This trial shows that delivery of a bespoke smoking cessation 
intervention to people with severe mental illness is feasible, 
with good levels of engagement with services compared with 
usual care. The use of smoking cessation interventions was 
much higher for people who received the bespoke cessation 
programme than among those who had usual care. 
We biochemically verified that over twice as many patients who 
received the bespoke cessation intervention had quit smoking 
at 6 months than those who received usual care. At 12 months, 
more patients in the intervention group had quit than those in 
the control group had, but the difference was not significant. 
We also noted some short-term improvements in self-reported 
physical health and no deterioration in mental health.
Implications of all the available evidence
Based on the results of our systematic reviews and this trial, 
clinicians should always ask people with severe mental illness 
about their desire to quit and ensure onward referral to the 
most suitable local smoking cessation service. Our research 
supports the provision of smoking cessation services specially 
designed for people with mental illnesses to address the high 
levels of smoking and the levels of unmet need for people with 
severe mental illness.
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Introduction
People with severe mental illnesses, such as schizo­
phrenia and bipolar disorder, are more likely to smoke 
and to smoke more heavily than the general population.1,2 
People with severe mental illness usually begin smoking 
at an earlier age and they usually smoke more cigarettes 
a day than smokers without severe mental illness.3,4 
Smokers with severe mental illness smoke each cigarette 
more intensely, extracting more nicotine per cigarette,5 
are more nicotine depen dent, more likely to develop 
smoking­related illnesses, and less likely to receive help 
to quit than the general population of smokers.6
Smoking is part of the culture of mental health 
services, both among staf and patients.7 This culture 
might be part of why mental health services have not 
historically increased eforts to develop and deliver 
improved smoking cessation treatments for this group 
of patients. Many believe smoking relieves depression 
and anxiety,8 but the opposite is true;9 smoking 
contributes to the general poor physical health of those 
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with severe mental illnesses. Cohort studies10 have shown 
that people with severe mental illnesses, such as 
schizophrenia, on average die 20–25 years earlier than 
those without severe mental illnesses, and that smoking 
is the most important modiiable risk factor for this 
health inequality.
Public health guidance issued by the UK National 
Institute for Health and Care Excellence (NICE) in 201311 
highlights the need for innovative approaches for this 
population to decrease this inequality. Guidance stresses 
that mental health services should become completely 
smoke free, and that all people who use mental health 
services should be given full access to smoking cessation 
interventions. However, little speciic guidance exists on 
how smoking cessation services should be provided and 
in what way smoking cessation interventions might 
need to be adapted for those with severe mental illness. 
Trial­based evidence suggests that people with severe 
mental illness are able to give up smoking and that 
behavioural and pharmacological interventions to aid 
quitting might be as efective for people with severe 
mental illness as for the general population.12 However, 
people with severe mental illness do not generally access 
generic smoking cessation services when they have been 
ofered in the UK National Health Service (NHS).13 In 
the general popu lation, the prevalence of smoking is 
decreasing, but little shift has been seen in the past 
decade in the prevalence among people with severe 
mental illnesses.14
To address this widening health inequality, we designed 
a smoking cessation intervention speciically for people 
with severe mental illnesses, incorporating evidence­
supported techniques to change behaviour and pharma­
cotherapy.15,16 We have previously reported the results of 
the Smoking Cessation Intervention for Severe Mental 
Illness (SCIMITAR) pilot trial,17 with acceptable levels of 
engagement and preliminary evidence of efectiveness. 
We now report the results of the full trial (SCIMITAR+) 
to examine the clinical efectiveness of a combined 
behavioural and pharmacological smoking cessation 
intervention for people with severe mental illnesses.
Methods 
Study design and participants
In this randomised, controlled trial, which used a 
pragmatic design,18 we recruited patients from 16 primary 
care and 21 community­based mental health sites in 
the UK (full list of mental health trusts is in appendix). 
Participants were made aware of the trial by members of 
the clinical team at each study site, either face to face or by 
personalised letter of invitation. The SCIMITAR+ study 
protocol has previously been published elsewhere.19 Ethical 
approval was granted by the National Research Ethics 
Service Committee, Yorkshire and the Humber–Leeds 
East Research Ethics Committee (reference 15/YH/0051).
Patients were eligible if they were aged 18 years or 
older, had severe mental illness, smoked at least ive 
cigarettes per day, and expressed an interest in cutting 
down or quitting smoking. No agreed deinition of severe 
mental illness exists, so we adopted a pragmatic 
deinition used in UK primary care20—ie, a documented 
diagnosis of schizophrenia, delusional or psychotic 
illness (corresponding with categories F20.0–20.9 and 
F22.0–22.9 from the 10th revision of the International 
Classiication of Diseases [ICD­10]), or bipolar disorder 
(ICD­10 F31.0–31.9). This diagnosis needed to have been 
made by a specialist in mental health services and 
documented in either primary care records or psychiatric 
notes before recruitment. Exclusion criteria were 
pregnancy and breastfeeding, substantial comorbid drug 
or alcohol problems (as ascertained by the primary care 
physician or mental health worker), non­English 
speakers, currently receiving advice from a stop smoking 
advisor, and lack of capacity to consent.
Randomisation and masking 
Participants were randomly assigned to either the 
bespoke smoking cessation service (intervention) or 
usual care (control). We used a secure telephone 
randomisation service run by the York Trials Unit 
(University of York, York, UK). Simple randomisation 
was used with a computer­generated random number 
sequence. Researchers (PH, SC, TM, TS, EB, PB, SB, 
DBr, TC, AC, CC, DC, ED, KE, HH, WK, LN, EN, HO, 
JRea, C­BR­H, KS, AS, and CV) phoned the service once 
the participant had consented and completed baseline 
assessments. Once given the details of the participant’s 
allocation, the researcher immediately informed them of 
their allocation. A letter was sent to the participant’s 
primary care physician and mental health specialist 
detailing their allocation and subsequent smoking 
cessation management. Due to the nature of the 
intervention, participants, mental health staf, primary 
care physicians and researchers (PH, SC, TM, TS, EB, 
PB, SB, DBr, TC, AC, CC, DC, ED, KE, HH, WK, LN, EN, 
HO, JRea, C­BR­H, KS, AS, and CV) were not masked to 
treatment allocation. Statistical analyses were blinded to 
treatment allocation.
Procedures 
Once participants had consented to take part in the trial, 
they were asked to complete baseline questionnaires 
that comprised questions on general health; 
demographics; smoking status and smoking history; 
use of e­cigarettes; and health service use questions;. 
Patients also answered questions from the FagerstrÖm 
Test of Nicotine Dependence (FTND),21 Motivation 
to Quit (MTQ)22 questionnaire, Patient Health 
Questionnaire­9 (PHQ­9),23 Generalised Anxiety 
Disorder­7 (GAD­7) questionanire,24 EuroQol ive­
dimensional ive­level (EQ­5D­5L)25 questionnaire, and 
12­Item Short­Form Health Survey (SF­12).26 Additionally, 
height and weight measurements were taken to calculate 
participants’ body­mass index (BMI) and a carbon 
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monoxide reading of their exhaled breath was obtained 
by use of a carbon monoxide monitor (piCO smokerlyzer, 
Bedfont Scientiic, Maidstone, UK). These baseline 
measurements were done at NHS sites or in the 
participant’s home by the study research staf (PH, SC, 
TM, TS, EB, PB, SB, DBr, TC, AC, CC, DC, ED, KE, HH, 
WK, LN, EN, HO, JRea, C­BR­H, KS, AS, and CV).
All participants in the trial received usual care and 
had access to the full range of smoking cessation 
treatments that were ofered by their local NHS trust. 
Under usual care, people with severe mental illness 
were able to access smoking cessation services provided 
by their primary care physician or in a locally­provided 
service not speciically designed for people with severe 
mental illness, at no direct cost. They were also able 
to access a free telephone helpline (the Smokefree 
National Helpline) that ofers smoking cessation advice. 
All participants remained under the care of their 
primary care physician and continued to receive their 
usual service from the mental health team throughout 
the trial.
Participants allocated to the bespoke smoking ces sation 
group were ofered a structured smoking cessation 
intervention delivered by a trained mental health smoking 
cessation practitioner. The smoking ces sation practitioners 
were generally experienced mental health nurses who 
worked in conjunction with the participant and the 
participant’s primary care physician or mental health 
specialist to provide an individually tailored smoking 
cessation service. The intervention was delivered according 
to the Manual of Smoking Ces sation (developed by the 
National Centre for Smoking Cessation Training [NCSCT], 
UK)27 with several adap tations to cater for people with 
severe mental illness. These adaptations included making 
several assess ments before setting a quit date, ofering 
nicotine replacement before setting a quit date (ie, cut 
down to quit),15,28 recognising the purpose of smoking in 
the context of a person’s mental illness, providing home 
visits, providing additional face­to­face support after an 
un successful quit attempt or relapse, and informing the 
primary care physician and psychiatrist of a successful 
quit attempt, such that they can review doses of anti­
psychotic medication if their metabolism changes. The 
smoking cessation practi tioners were drawn from local 
NHS staf and attended one of a number of 2­day training 
events run by study staf at the University of York (York, 
UK), University of Manchester (Manchester, UK), and 
University College London (London, UK) based on the 
NCSCT’s practitioner training with some additional 
training on speciic adaptations for people with severe 
mental illness. The smoking cessation practitioner 
advised the patients on a range of pharma cological aids 
for smoking cessation (eg, nicotine replacement, 
varenicline) and liaised with their primary care physician 
to ensure that these options were ofered in line with 
patient choice. The full range of nicotine replacement and 
smoking cessation products from the British National 
Formulary were made available to participants.29 However, 
the inal prescription of treatments was left to the 
discretion of the primary care physician. Participants were 
ofered up to 12 individual face­to­face sessions in their 
home or NHS premises lasting approximately 30 min. 
The intervention had been developed and tested in the 
context of a pilot randomised controlled trial and the full 
details have been published elsewhere.16,17 Participants 
were contacted and the treatment pro gramme initiated 
within 7 days of assign ment.
SCIMITAR+ was a pragmatic trial,18 and the com­
parator was the care that patients with severe mental 
illness would access under usual circumstances (ie, 
usual care). In the UK, all patients (including people 
with severe mental illness) have access to statutory 
smoking cessation services at no direct personal cost, 
which would include access to a smoking cessation 
counsellor who would administer evidence­supported 
treatments, including behavioural support and access to 
pharmacotherapy. Research has shown that the uptake 
of such services is quite low for patients with severe 
mental illness13 and we anticipated from the outset that 
treatment accessed under usual care would fall short of 
evidence­supported guidelines.11 Participants allocated to 
the usual care group were advised to quit, see their primary 
care physician, and contact local NHS stop smoking 
services. Thereafter, no additional treatment was ofered 
in the context of the SCIMITAR+ trial. We measured the 
degree of engagement with statutory smoking cessation 
services to see if control participants sought help to quit 
after they received this advice.
12 months after treatment allocation, we contacted the 
primary care physician of each participant to obtain 
primary care records, which were screened for details of 
any nicotine replacement treatment or other smoking 
cessation products that had been prescribed to par­
ticipants in the study. Participants were also asked about 
their purchase of over­the­counter products during 
follow­up, as part of the health­service use questionnaire, 
and we recorded nicotine therapy use via self­report.
Participants were followed up at 6 and 12 months after 
treatment allocation. At the two follow­up timepoints, 
participants completed the same series of questionnaires 
as at baseline apart from the demographics questionnaire. 
Additionally, participants were asked to provide a carbon 
monoxide breath measure and have their height and 
weight measured. When possible, participants were 
followed up face to face, but if not possible they were 
followed up by phone or by postal questionnaire.
The FTND 21 is a six­item questionnaire measuring 
nicotine dependence.  Item scores are summed to give 
a total score between 1 and 10, where a score of 1–2 
indicates low dependence, 3–4 indicates low­to­moderate 
dependence, 5–7 indicates moderate dependence, and 
8–10 indicates high dependence. The MTQ questionnaire22 
is a four­item questionnaire measuring an individual’s 
motivation to quit smoking. Scores are from 4 to 19 by 
For the NHS Smokefree website 
see https://www.nhs.uk/
smokefree/help-and-advice/
support
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summing the responses to each item, where a higher 
score indicates greater motivation to quit. The PHQ­923 
instrument measures severity of depression.  This nine­
item questionnaire is scored from 0 to 27, and a higher 
scores indicates more severe depressive symptoms. 
The GAD­7 questionnaire24 is a seven­item instrument 
designed to measure severity of anxiety, scored from 0 to 
21, with a higher score indicating more severe anxiety. 
The SF­1226 consists of two subscales: a physical com­
ponent and a mental component, both scored from 
0 to 100, with 0 indicating the lowest level of health and 
100 the highest level of health measured by the scale.
Adverse events were recorded at 6 months and 
12 months. As part of the follow­up questionnaires par­
ticipants were asked about their health service use, and if 
a participant reported having a suspected serious adverse 
event, an independent reviewer was contacted to provide a 
review of the events and determine whether the event was 
likely to have been related to the trial and whether or not it 
was expected. An event was classed as serious if it met any 
of the following criteria: life threatening (ie, event in 
which patient is at risk of death at the time of the event 
occurring); fatal; requiring unplanned admission to 
hospital resulting in an inpatient stay or extension of 
hospital stay beyond what was expected (ie, patient 
operated on as an outpatient but remains in hospital 
overnight); resulting in persistent or substantial disability 
or incapacity; resulting in a congenital abnormality or 
birth defect; or any other medical condition not listed here 
that might require medical or surgical intervention to 
prevent the above criteria occurring.
Outcomes 
The primary outcome was smoking cessation at 
12 months after randomisation. A successful quitter was 
deined as someone with a carbon monoxide measure­
ment below 10 parts per million (ppm),30 indicating no 
smoking in the past 12 h, and who reported that they 
had not smoked (responding “not even a puf” to the 
question “Have you smoked in the past week?”) in the 
past week (ie, 7­day point prevalence abstinence at 
12 months with carbon monoxide <10 ppm).
Secondary outcomes were biologically veriied smoking 
cessation at 6 months; and number of cigarettes smoked 
per day using the FTND21 and MTQ questionnaire;22 
general and mental health functioning determined via the 
PHQ­9,23 the GAD­7 questionnnaire,24 and SF­12;26 and 
BMI, all measured at 6 and 12 months. Additional 
outcomes of interest were health service use for both 
treatment groups and adherence to smoking cessation 
advice for the intervention group only. Another secondary 
outcome  was health state utilities measured by use of the 
EQ­5D­5L questionnaire25 to undertake a cost–utility 
analysis, and these results will be presented elsewhere as 
part of the health economic evaluation.
We also compared the prescribed nicotine replacement 
treatment or other smoking cessation products between 
participants in the intervention and usual care groups, 
which will be presented as part of the health economic 
analysis.
Safety was assessed in all participants who were 
allocated to treatment, with assessment of adverse events 
and ascertaining their association with the intervention. 
BMI, health service use, and anxiety measured by use of 
the GAD­7 questionnaire were included in the protocol 
from the beginning of the study but omitted from the 
original ISRCTN registration in error.
Statistical analysis
We used descriptive statistics to show the baseline 
demo graphic data and smoking status of the participants 
who were enrolled, by treatment group. All statistical 
tests were two­sided at the 5% signiicance level. We 
made no adjustment for multiplicity because a clear 
primary outcome was deined and all other outcomes 
served as secondary investigations.
We used results from the SCIMITAR pilot trial17 and 
earlier systematic reviews12 to inform the sample size 
calculation. This study was powered at 80% to detect a 
relative 1·7 times increase in quitting, assuming a 20% 
incidence of quitting among control participants, equal 
randomisation, and a two­sided α level of 0·05. Allowing 
for 20% loss to follow­up at 12 months, we calculated 
that 393 participants needed to be recruited and 
randomised. We therefore proposed to conservatively 
recruit 400 participants overall.
We present the proportion of participants who were 
veriied as quitters by use of carbon monoxide measure­
ments at 6 months and 12 months with an unadjusted 
absolute risk diference and 95% CI, and we analysed 
these outcomes on an intention­to­treat basis via 
separate mixed­efect logistic regression models (for 
each timepoint), adjusted for baseline smoking severity 
(self­reported number of cigarettes smoked per day), 
with site as a random efect. We present the adjusted 
odds ratio (OR), and corresponding two­sided 95% CI 
and p value for the treatment efect at months 6 and 12. 
As sensitivity analyses, we also did multiple imputation 
to account for missing data,31 imputed self­reported 
quitting when biochemically veriied quitting data were 
not available, and assumed that people with missing 
data were still smoking. A full description of the planned 
and completed statistical analysis are in the appendix.
We compared the number of cigarettes smoked per 
day (reported as part of the FTND) at 6 and 12 months 
between the two groups using a mixed­efect negative 
binomial regression model using the log link function, 
adjusted for baseline smoking severity, treatment 
group, assessment timepoint (6 or 12 months), and a 
treatment group­by­time interaction term, and site as a 
random efect. We provide incidence rate ratios (IRRs) 
and their associated 95% CIs and p values for this 
measure. We compared scores for FTND, MTQ, PHQ­9, 
GAD­7, SF­12 physical component, SF­12 mental 
See Online for appendix
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component, and BMI between treatment groups using 
a covariance pattern linear­mixed model. The outcome 
modelled was total score at 6 and 12 months. Each 
model included the following as ixed efects: baseline 
score, baseline smoking severity, treatment group, 
assessment timepoint, and a treatment group­by­time 
inter action term, and site as a random efect. We report 
predicted means for each group and the adjusted mean 
diference (with 95% CI and p value) between treatment 
groups at 6 and 12 months. We did a post­hoc, non­
randomised comparison of BMI between quitters and 
non­quitters at 6 and 12 months using a mixed­efect 
linear model adjusting for baseline BMI, baseline 
smoking severity, and treatment group, with site as a 
random efect. For participants in the inter vention 
group, we summarised treatment session data in­
cluding the number of sessions attended, the mode 
of those sessions (eg, face to face, phone visits) and 
the duration and location (eg, participant’s home) of 
the sessions.
We did all analyses using Stata version 15. This trial 
was prospectively registered with the ISRCTN registry 
(ISRCTN72955454).
Role of the funding source
The funder of this study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had inal responsibility for 
the decision to submit for publication.
526 participants enrolled
265 assigned to bespoke smoking cessation 
intervention
         234 received intervention
            31 did not receive intervention
                  27 no sessions arranged
                    3 first session arranged but
                        participant did not attend
                    1 first session arranged but was
                       cancelled
236 followed up at 6 months*
         234 provided self-reported smoking status
         228 provided carbon monoxide measurement 
         226 provided both self-reported smoking  
         status and carbon monoxide measurement 
   10 did not complete follow-up at 6 months† 
227 followed up at 12 months*
        226 provided self-reported smoking status
        224 provided carbon monoxide measurement 
        223 provided both self-reported smoking status 
       and carbon monoxide measurement 
   14 did not complete follow-up at 12 months‡
223 included in primary outcome analysis
  42 excluded from primary outcome analysis
        3 missing 12-month carbon monoxide
           measurement
        1 missing self-reported smoking status
     38 missing 12-month carbon monoxide
           measurement and self-reported smoking 
  status
19 withdrew from study
5 withdrew from study
261 assigned to usual care
         261 received usual care treatment
230 followed up at 6 months*
         229 provided self-reported smoking status
         218 provided carbon monoxide measurement 
         217 provided both self-reported smoking 
        status and carbon monoxide measurement 
   13 did not complete follow-up at 6 months† 
233 followed up at 12 months*
         223 provided self-reported smoking status
         219 provided carbon monoxide measurement 
         219 provided both self-reported smoking status 
         and carbon monoxide measurement 
   16 did not complete follow-up at 12 months‡ 
219 included in primary outcome analysis
  42 excluded from primary outcome analysis
        4 missing 12-month carbon monoxide
            measurement
      38 missing 12-month carbon monoxide
            measurement and self-reported smoking 
   status
18 withdrew from study
4 withdrew from study
Figure: Trial profile
*Defined as providing some follow-up outcome data at this timepoint. †These participants were contacted for follow-up at 6 months because they had not formally 
withdrawn before this timepoint. They were not considered lost to follow-up beyond this point and were contacted again for follow-up at 12 months unless they had 
subsequently withdrawn. ‡These participants were contacted for follow-up at 12 months because they had not formally withdrawn before this timepoint, 
but did not provide any outcome data.
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Results 
Between Oct 7, 2015, and Dec 16, 2016, 526 eligible 
participants were randomly assigned to the intervention 
group (n=265) or usual care group (n=261; igure). 
504 (96%) participants were recruited via direct referrals 
via an NHS mental health trust, and 22 (4%) via mailouts 
to potentially eligible participants at primary care sites. 
We did not record the number of invitations that were 
sent out in all settings. The most common severe mental 
disorders were schizophrenia or other psychotic illness 
(n=343 [65%]), bipolar disorder (n=115 [22%]), and 
schizoafective disorder (n=66 [13%]). 309 (59%) partici ­
pants were male, the median age was 47·2 years 
(IQR 36·3–54·5), and most participants were overweight 
(median BMI 29·3 [IQR 25·0–33·7]), with long smoking 
histories (mean duration of smoking 29·9 years [SD 12·9]), 
and high nicotine dependence (mean 24·0 cigarettes per 
day [SD 13·2]). Most participants (439 [83%]) felt that 
smoking had negatively afected their health, and 
373 (71%) reported that they had been advised to stop 
smoking by their general practitioner; baseline demo­
graphic character istics are shown in table 1.
At 12 months, 84 (16%) participants did not attend 
follow­up or had missing data, and 442 (84%) provided 
sustained quit data (self­reported smoking status and 
carbon monoxide reading), of whom 223 (50%) were in 
the intervention group and 219 (50%) were in the usual 
care group. 34 (15%) of 223 participants (13% of 265 
assigned to group) in the intervention group, and 22 (10%) 
of 219 (8% of 261 assigned to group) in the usual care 
group had quit smoking (risk diference 5·2%, 95% CI 
–1·0 to 11·4).  The unadjusted OR was 1·6 (95% CI 0·9 to 
2·9; p=0·10), and the adjusted OR was 1·6 (0·9 to 2·8, 
p=0·12).
At 6 months, 443 (84%) of 526 participants provided 
sustained quit data (n=226 intervention group, n=217 
usual care group). 32 (14%) of 226 participants (11% of 
265 assigned to group) in the intervention group, and 14 
(6%) of 217 (5% of 261 assigned to group) in the usual 
care group had quit (risk diference 7·7%, 95% CI 2·1% 
to 13·3%). The unadjusted OR was 2·4 (95% CI 1·2 to 
4·6; p=0·010) and the adjusted OR was 2·4 (95% CI 1·2 
to 4·7; p=0·010).
At 6 months, only three participants (all in the usual care 
group) reported they were abstinent but were above the 10 
ppm threshold. At 12 months, 57 reported “not smoking a 
puf” in the past week (n=35 in intervention group, n=22 
in usual care group), of whom one in the intervention 
group did not provide a carbon monoxide measurement 
and the other 56 were all below the 10 ppm threshold. 
Secondary outcomes were summarised by group and the 
results are shown in tables 2 and 3. The IRR for number of 
cigarettes smoked per day at 6 months was 0·90 (95% CI 
0·80 to 1·01; p=0·079), and at 12 months was 1·00 (0·89 to 
1·13; p=0·95). Results of the FTND and MTQ showed a 
trend towards the intervention group at both 6 months and 
12 months, but it was not signiicant. When measuring 
Intervention 
group (n=265)
Control group 
(n=261)
Total  
(n=526)
Sex
Male 159 (60%) 150 (57%) 309 (59%)
Female 105 (40%) 111 (43%) 216 (41%)
Transgender 1 (<1%) 0 1 (<1%)
Age, years
Mean 46·5 (12·5) 45·5 (11·7) 46·0 (12·1)
Median 47·6 
(35·6–55·2)
46·6 
(36·5–53·8
47·2 
(36·3–54·5)
Body-mass index,* kg/m²
Mean 30·2 (7·1) 29·7 (6·3) 29·9 (6·7)
Median 29·0 
(25·1–34·0)
29·4 
(24·9–33·3)
29·3 
(25·0–33·7)
Most recent diagnosis
Bipolar disorder 59 (22%) 56 (21%) 115 (22%)
Schizoaffective disorder 25 (10%) 41 (16%) 66 (13%)
Schizophrenia 138 (52%) 125 (48%) 263 (50%)
Other psychotic disorder 41 (16%) 39 (15%) 80 (15%)
Cigarettes usually smoked (per day)
Mean 24·7 (13·5) 23·2 (12·8) 24·0 (13·2)
Median 20 (16–30) 20 (15–30) 20 (15–30)
Smoking duration,† years
Mean 30·7 (13·2) 29·0 (12·5) 29·9 (12·9)
Median 31·9 
(20·6–40·6)
29·3 
(20·4–39·1)
30·6 
(20·5–39·7)
Exhaled carbon monoxide,‡ ppm
Mean 24·9 (15·4) 24·3 (15·1) 24·6 (15·2)
Median 22 (14–33) 21 (14–31) 21 (14–32)
Alcohol consumption§
Yes 141 (53%) 140 (53·6%) 281 (53%)
No 122 (46%) 121 (46·4%) 243 (46%)
Do you feel that smoking has affected the state of your health?
Yes 220 (83%) 219 (84%) 439 (83%)
No 45 (17%) 42 (16%) 87 (17%)
Advised to quit smoking by doctor
Yes 192 (72%) 181 (69%) 373 (71%)
No 73 (28%) 80 (31%) 153 (29%)
Recreational drug use¶
Yes 20 (8%) 25 (10%) 45 (9%)
No 244 (92%) 234 (90%) 478 (91%)
Data are n (%), mean (SD), and median (IQR). ppm=parts per million. *Data are 
missing for three participants in the control group and two in the intervention 
group. †Data are missing for one participant in the control group. ‡Data are 
missing for three participants in the control group and one in the intervention 
group. §Data are missing for two participants in the intervention group. ¶Data 
are missing for one participant in the control group and  one in the intervention 
group.
Table 1: Baseline characteristics and smoking history
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depression with the PHQ­9, we saw no between­group 
diference. Measuring anxiety with the GAD­7 question­
naire we found no diference between the groups. 
The SF­12 measured both physical and mental health 
using the physical component subscale and mental com­
ponent subscale. We saw evidence of improvement in 
physical health in the intervention group at 6 months, 
but this diference was not evident at 12 months (table 3). 
For mental health, we saw no diference between the 
groups at 6 or 12 months.
No diferences in BMI between the groups was 
seen at either timepoint (table 3). At 6 months, in a 
post­hoc non­randomised comparison between quitters 
veriied by carbon monoxide measurements (n=43) and 
those still smoking (n=376), quitters had a slightly higher 
mean BMI (mean 31·4 [SD 6·0]) than smokers did 
(mean 30·1 [SD 6·6]). The mean diference adjusting 
for baseline BMI, treatment allocation, and number of 
cigarettes smoked at baseline, with site as a random efect, 
was 1·3 (95% CI 0·2 to 2·5; p=0·0026). The diference at 
12 months was in the same direction but was smaller and 
non­signiicant (quitters [n=52] mean BMI 30·6 [SD 7·1] 
vs smokers [n=357] mean BMI 29·9 [SD 6·9]; adjusted 
mean diference 0·2, 95% CI –1·1 to 1·5; p=0·77).
234 (88%) of 265 intervention participants attended at 
least one treatment session. For these 234 participants, 
the mean number of sessions attended was 6·4 (SD 3·5; 
median 6, range 1–14). Sessions lasted an average of 
39 min (SD 17·2; median 35 min, range 5–120). Most 
(85% [1260 of 1483]) took place face to face, 4% (61) over 
the phone and 11% (162) via another mode (eg, web 
teleconference, email). 1202 (81%) sessions occurred at 
the participant’s home.
Prescription information was obtained from primary 
care sites for 160 (61%) participants in the control group 
and 156 (59%) in the intervention group. 147 (55%) 
participants in the intervention group and 97 (37%) in 
the control group recorded pharmacotherapy use via self­
report. By smoking cessation product, missing data 
ranged from 14% to 41% of participants per group, with 
Intervention group Control group
Baseline (n=265) 6 months (n=236) 12 months (n=227) Baseline (n=261) 6 months (n=230) 12 months (n=223)
Number of cigarettes
n 265 (100%) 188 (80%) 176 (76%) 261 (100%) 198 (86%) 191 (86%)
Mean 24·7 (13·5) 17·8 (12·7) 20·2 (12·3) 23·2 (12·8) 18·3 (10·0) 18·7 (12·1)
Fagerström Test for Nicotine Dependence
n 258 (97%) 185 (78%) 169 (74%) 254 (97%) 195 (85%) 186 (83%)
Mean 6·5 (2·0) 5·3 (2·1) 5·6 (2·0) 6·4 (1·9) 5·4 (2·0) 5·3 (2·3)
Motivation to Quit questionnaire
n 260 (98%) 217 (92%) 200 (88%) 259 (99%) 201 (87%) 200 (90%)
Mean 13·9 (2·7) 13·2 (3·4) 13·0 (3·3) 13·7 (2·6) 12·4 (3·1) 12·3 (3·4)
Patient Health Questionnaire-9
n 264 (>99%) 223 (94%) 213 (94%) 260 (>99%) 214 (93%) 211 (95%)
Mean 10·3 (6·7) 9·3 (6·7) 9·0 (6·7) 10·8 (6·6) 9·4 (6·4) 9·7 (6·7)
Generalised Anxiety Disorder-7 questionnaire
n 264 (>99%) 224 (95%) 214 (94%) 260 (>99%) 217 (94%) 212 (95%)
Mean 8·4 (6·2) 7·0 (5·9) 7·0 (6·3) 8·4 (6·1) 7·3 (5·8) 7·4 (6·0)
12-Item Short Form Health Survey
n 257 (97%) 214 (91%) 212 (93%) 256 (98%) 208 (90%) 207 (93%)
Physical component, mean 43·7 (10·4) 45·6 (9·8) 44·3 (10·1) 42·2 (11·0) 42·9 (11·0) 42·4 (11·4)
Mental component, mean 38·6 (12·6) 38·4 (13·1) 39·3 (11·9) 37·9 (11·7 38·9 (12·2) 38·9 (11·9)
Body-mass index, kg/m²
n 263 (99%) 216 (92%) 208 (92%) 258 (99%) 205 (89%) 201 (90%)
Mean 30·2 (7·1) 30·5 (7·0) 30·4 (7·2) 29·7 (6·3) 29·9 (6·0) 29·7 (6·7)
Recreational drug use
n 264 (>99%) 221 (94%) 214 (94%) 259 (99%) 212 (92%) 213 (96%)
Yes 20 (8%) 14 (6%) 14 (7%) 25 (10%) 22 (10%) 19 (9%)
No 244 (92%) 207 (94%) 200 (93%) 234 (90%) 190 (90%) 194 (91%)
Data are n (%) or mean (SD).
Table 2: Summary of secondary outcomes 
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the most missing data being for the prescription of 
varenicline (table 4). Among nicotine replacements 
therapies, nicotine patches were the most used 
medication in both groups. E­cigarettes were used by 
participants in both groups as a smoking cessation aid, 
with slightly more participants in the control group 
reporting use of e­cigarettes than those in the intervention 
group did. Varenicline was rarely prescribed; at the 
commencement of the SCIMITAR+ trial it was 
contraindicated for people with severe mental illness.
In our sensitivity analyses, in which we imputed self­
reported smoking status when carbon monoxide 
measurements were missing, the treatment efects were 
not substantially altered (6­month adjusted OR 2·6, 
95% CI 1·3–5·0, p=0·0046; 12­month adjusted OR 1·7, 
0·9–3·0, p=0·079). When assuming anyone else with 
missing smoking status data was a smoker, the 6­month 
adjusted OR was 2·6 (95% CI 1·4–5·0; p=0·004) and the 
12­month adjusted OR was 1·7 (0·9–2·9; p=0·081). 
Multiple chained imputation of missing data also gave 
similar results at both timepoints (6 months adjusted 
OR 2·4, 1·3–4·4, p=0·0067; 12 months adjusted OR 1·7, 
0·9–3·0, p=0·083).
Discussion
The main outcome of interest was whether smoking 
cessation could be achieved using a biochemical 
measure, and the SCIMITAR+ trial used long­term 
quitting as measured at 12 months after randomisation 
as its primary endpoint. The diference in the proportion 
of participants who quit was not signiicant at 1 year. This 
inding is in line with research in the general population 
that shows that long­term cessation of smoking is 
di cult to achieve and remains a challenge in treatment 
for nicotine dependence in any population.32 
The inluence of the bespoke smoking cessation 
intervention was seen in the secondary outcomes. We 
found that smoking cessation can be achieved among 
people with severe mental illnesses. Compared with 
usual care, the provision of a bespoke smoking cessation 
intervention increased engagement and the chances of 
successful quitting as estimated by a bio chemically 
veriied outcome measure. The chances of successful 
quitting at 6 months after randomisation among those 
who received the bespoke smoking cessation intervention 
were more than twice those who received usual care. We 
also found an improvement in short­term physical health 
(measured by use of the SF­12) and trend towards 
decreased numbers of cigarettes smoked per day at 
6 months and increased motivation to quit at 12 months. 
We also found no diferences between the groups on 
measures of mental health, which included depression 
and anxiety. These indings provide sup portive evidence 
that ofering a smoking cessation intervention is not 
detrimental to mental health
SCIMITAR+ was a pragmatic trial18 and our comparator 
was therefore usual care. As such, the treatment that 
Intervention group Control group Difference p value
Number of cigarettes per day
Month 6 17·7 (15·8 to 19·5) 18·0 (16·5 to 19·4) IRR 0·90 (0·80 to 1·01) 0·079
Month 12 19·7 (17·8 to 21·7) 18·7 (16·9 to 20·4) IRR 1·00 (0·89 to 1·13) 0·95
Fagerström Test for Nicotine Dependence
Month 6 5·25 (5·00 to 5·50) 5·43 (5·19 to 5·67) –0·18 (–0·53 to 0·17) 0·32
Month 12 5·42 (5·14 to 5·70) 5·43 (5·16 to 5·69) –0·01 (–0·39 to 0·38) 0·97
Motivation to Quit questionnaire
Month 6 13·1 (12·6 to 13·5) 12·5 (12·0 to 12·9) 0·58 (–0·01 to 1·17) 0·056
Month 12 12·9 (12·4 to 13·4) 12·3 (11·8 to 12·7) 0·64 (0·04 to 1·24) 0·038
Patient Health Questionnaire-9
Month 6 9·6 (8·7 to 10·4) 9·4 (8·5 to 10·2) 0·20 (–0·85 to 1·24) 0·72
Month 12 9·3 (8·4 to 10·1) 9·4 (8·5 to 10·2) –0·12 (–1·18 to 0·94) 0·82
Generalised Anxiety Disorder-7 questionnaire
Month 6 7·0 (6·3 to 7·7) 7·4 (6·7 to 8·1) –0·32 (–1·26 to 0·62) 0·50
Month 12 7·1 (6·4 to 7·8) 7·2 (6·5 to 7·9) –0·10 (–1·05 to 0·86) 0·84
12-Item Short Form Health Survey
Mental component
Month 6 37·9 (36·2 to 39·5) 38·6 (36·9 to 40·3) –0·73 (–2·82 to 1·36) 0·49
Month 12 38·6 (37·0 to 40·1) 39·0 (37·4 to 40·5) –0·41 (–2·35 to 1·53) 0·68
Physical component
Month 6 45·2 (44·1 to 46·3) 43·5 (42·4 to 44·6) 1·75 (0·21 to 3·28) 0·026
Month 12 43·6 (42·4 to 44·8) 43·0 (41·8 to 44·2) 0·59 (–1·07 to 2·26) 0·48
Body-mass index
Month 6 30·3 (29·8 to 30·8) 30·1 (29·6 to 30·6) 0·16 (–0·54 to 0·85) 0·65
Month 12 30·2 (29·5 to 30·8) 29·9 (29·3 to 30·5) 0·25 (–0·62 to 1·13) 0·57
Data are mean and adjusted mean difference, unless otherwise stated, with 95% CIs in parentheses. IRR=incidence rate 
ratio. 
Table 3: Adjusted means and group differences for secondary outcomes
Intervention group (n=265) Control group (n=261)
Used 
medication
Did not use 
medication 
Missing data Used 
medication
Did not use 
medication 
Missing data
Patch 90 (34%) 128 (48%) 47 (18%) 52 (20%) 171 (66%) 38 (15%)
Gum 28 (11%) 190 (72%) 47 (18%) 16 (6%) 207 (79%) 38 (15%)
Lozenge 29 (11%) 190 (72%) 46 (17%) 15 (6%) 209 (80%) 37 (14%)
Microtab 2 (1%) 215 (81%) 48 (18%) 0 223 (85%) 38 (15%)
Inhalator 34 (13%) 183 (69%) 48 (18%) 13 (5%) 211 (81%) 37 (14%)
Nasal spray 11 (4%) 206 (78%) 48 (18%) 2 (1%) 221 (85%) 38 (15%)
Mouth spray 37 (14%) 180 (68%) 48 (18%) 18 (7%) 205 (79%) 38 (15%)
Varenicline* 7 (3%) 149 (56%) 109 (41%) 7 (3%) 153 (59%) 101 (39%)
E-cigarette 95 (36%) 116 (44%) 54 (20%) 102 (39%) 101 (39%) 58 (22%)
Data are n (%). The proportions do not add up to 100% because some participants used multiple aids. Use of smoking 
cessation aids is a combination of self-report and prescription data. *Higher rates of missing data for varenicline, because 
this medication was not recorded by self-report and medical records were the only source for this information.
Table 4: Proportion of participants who used quit smoking aids during 12 months of follow-up 
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is ofered under conditions of usual care will vary by 
site, and will often fall short of the ideal or that recom­
mended in evidence­supported guidelines.11 Previous 
research has shown that the uptake of smoking cessation 
services by people with severe mental illnesses is lower 
than that of the general population,13 and we also found 
this lower uptake under conditions of usual care in the 
SCIMITAR+ trial. An important inding was that the 
provision of a bespoke service had a direct efect on 
the proportion of participants who engaged with the inter­
vention and received efective pharma cotherapy. Notably, 
few participants were prescribed the most efective form of 
pharmacotherapy, varenicline, despite this medication 
having now been shown to be safe and efective among 
people with severe mental illness.33 This paucity of pre­
scription might be because varenicline has been thought 
to be associated with suicidality or deterioration in mental 
health.34
To our knowledge, this is the irst large­scale 
randomised controlled trial in the UK of a combined 
behavioural and pharmacological intervention designed 
for people with severe mental illnesses. Trials to date have 
been small scale, with short periods of follow­up, and 
focused on pharmacological treatments with little 
consideration of behavioural approaches.35 We adapted 
and enhanced an evidence­supported smoking cessation 
strategy that was developed for and forms the mainstay of 
successful stop smoking services in the UK.36 This 
structured intervention was delivered by a mental health 
professional and a so­called cut down to quit approach 
was also ofered.37 The results of the SCIMITAR+ trial, 
alongside other trials38 and evidence from systematic 
reviews12,33 of the safety and efectiveness of pharma­
cological treatments for nicotine dependence in people 
with mental illness, are accumulating evidence of the 
efectiveness of smoking cessation interventions for 
this disadvantaged group. Evidence is also emerging 
that smoking cessation can be delivered in inpatient 
settings,39,40 although the SCIMITAR+ trial did not include 
such populations. Further research is needed to examine 
whether this intervention could be adapted to be delivered 
in inpatient environments where patients often abstain 
from smoking for the irst time.
The results of the SCIMITAR+ trial will be helpful in 
informing clinical practice, since we have shown that 
quitting can be achieved for people who use mental 
health services just as it can for the general population 
of smokers. Clinicians should therefore ask all of 
their patients about smoking status and ofer referrals 
to efective smoking cessation services, such as those 
described in this study. On the basis of the results of 
this trial and systematic review evidence,9,35 smoking 
cessation is likely to be either beneicial or not harmful 
to mental health. Decision makers should consider com­
missioning and providing intensive smoking cessation 
services as a core feature of comprehensive mental 
health care to ensure the needs of people within mental 
health services are met. Evidence­supported guidance, 
such as that ofered by NICE regarding tobacco policies 
and the provision of smoking cessation inter ventions in 
mental health services,11 have not been widely im­
plemented. The intervention described in this study 
(alongside other such models of care41,42) could form a 
template for mental health services and would ensure 
that they are compliant with NICE guidance. We would 
also suggest that clinical services should ensure longer­
term follow­up to maintain the proportion of patients 
who quit smoking in the short term observed in this 
study, although more research is still needed in this 
area. A further issue for implementation is the use of 
e­cigarettes. The SCIMITAR+ trial coincided with a 
general increase in the use of e­cigarettes through out 
the population. This topic is one of substantial debate43 
and consensus is emerging that e­cigarettes are safer 
than tobacco.44
This trial had several limitations. First, 16% of par­
ticipants were lost to follow­up or had missing data for 
the primary outcome at 12 months; however, this loss 
was lower than in our pilot trial17 and the loss to follow­
up was non­diferential. Second, more participants in 
the usual care group had quit smoking at 12 months 
than was hypothesised in the sample size calculation 
(10% vs 20%), and the actual percentage increase was 
lower (5% actual vs 14% predicted). Therefore, although 
the trial recruited more participants than originally 
planned and loss to follow­up was lower than anticipated 
(16% vs 20%), the trial was ultimately underpowered to 
detect a diference in the proportion of patients who quit 
from 10% to 15%. Third, di culties in ensuring that 
some participants received pharmacological treatment 
because of changes in the way that smoking cessation 
services are com missioned and in some areas primary 
care physicians were unwilling to prescribe nicotine 
replacement therapy because of smoking cessation 
services being contracted out to third parties who were 
unwilling to prescribe for participants unless they 
entered their service. Such attitudes could lead to 
di culties were in implementing the results of the 
SCIMITAR+ trial, and so we would recommend that 
local services put robust mechanisms in place to remove 
bar riers to the provision of medication, including 
varenicline.
In the face of substantial health inequalities for people 
with severe mental illness, smoking is the most important 
modiiable risk factor for poor health and reduced life 
expectancy.11,45 In this study, we have shown that people 
with severe mental illnesses more readily engage with a 
bespoke intervention than usual care, and that the inter­
vention results in an increased proportion of patients 
who quit at 6 months. Health systems should provide 
smoking cessation interventions that are responsive to 
the needs of people who use mental health services. 
Further research is needed to establish how long­term 
quitting can be supported.
Articles
www.thelancet.com/psychiatry   Vol 6   May 2019 389
Contributors
SG and EP wrote the original protocol. TB, CH, EH, TH, SK, ML, DO, 
EP, SP, JRei, and SG, were co­applicants on the Health Technology 
Assessment application. CA, DBa, DBr, TB, SC, CF, CH, EH, MH, PH, 
TH, SK, JL, ML, DO, SP, JRei, and SG reined the protocol. SG was the 
chief investigator and oversaw the study. EP was the trial manger. CF did 
the clinical analysis and CH oversaw the analysis. JL designed and 
undertook the economic analysis in conjunction with SP. DBa supervised 
the delivery of the intervention and CA, SC, TM, PH, and TS were trial 
coordinators for the study. TM, TS, EB, PB, SB, DBr, TC, AC, CC, DC, 
ED, KE, HH, WK, LN, EN, HO, JRea, C­BR­H, KS, AS, and CV recruited 
participants to the study, provided feedback on the recruitment methods, 
and helped reine the study procedures. PP and SR helped reine the 
study procedures. The writing team consisted of EP, CA, DBa, SC, CF, 
PH, JL, and SG, who drafted the report. All authors were responsible for 
critical review of the manuscript for important intellectual content and all 
authors read and reviewed the transcript.
Declaration of interests
We declare no competing interests.
Data sharing
De­identiied individual­participant data that underlie the results 
presented in this Article, the study protocol, statistical analysis plan, and 
analytical code will be available to investigators for individual participant 
data meta­analyses that have been approved by independent review 
committees. Data will be available from the publication date of this 
Article, with no end date. Proposals for use of data and requests for 
access should be directed to simon.gilbody@york.ac.uk. To gain access, 
data requestors will need to sign a data access agreement with the study 
sponsor (University of York, York, UK).
Acknowledgments
We thank the participants for taking part in the trial, the primary care 
physicians, and secondary and tertiary care staf for recruiting 
participants to the study and completing trial documentation, and the 
Trial Steering Committee and Data Monitoring and Ethics Committee 
members for overseeing the study. We thank Andy McEwan for his 
support and on the use of evidence supported smoking cessation 
interventions and their adaptation to people with severe mental illness. 
This study was funded by the National Institute for Health Research 
(NIHR) Health Technology Assessment Programme (project number 
11/136/52); SG, SP and ML were funded by the NIHR Collaboration for 
Leadership in Applied Health Research and Care Yorkshire and Humber. 
The views and opinions expressed herein are those of the authors and 
not necessarily those of the UK National Health Service, the NIHR, or 
the UK Department of Health and Social Care. We dedicate this trial to 
the memory of Prof Helen Lester who died in 2013 and collaborated on 
the early stages of the SCIMITAR+ trial; this study is a celebration of her 
abiding passion, work, and contribution to the care and wellbeing of 
people with severe mental illness and will be her lasting contribution.
References
1 Royal College of Physicians, Royal College of Psychiatrists. 
Smoking and mental health. London: Royal College of Physicians, 
Royal College of Psychiatrists, 2013.
2 Szatkowski L, McNeill A. Diverging trends in smoking behaviors 
according to mental health status. Nicotine Tob Res 2015; 17: 356–60.
3 Weiser M, Reichenberg A, Grotto I, et al. Higher rates of cigarette 
smoking in male adolescents before the onset of schizophrenia: 
a historical­prospective cohort study. Am J Psychiatry 2004; 
161: 1219–23.
4 Tsoi DT, Porwal M, Webster AC. Eicacy and safety of bupropion 
for smoking cessation and reduction in schizophrenia: systematic 
review and meta­analysis. Br J Psychiatry 2010; 196: 346–53.
5 Williams JM, Ziedonis DM, Abanyie F, Steinberg ML, Foulds J, 
Benowitz NL. Increased nicotine and cotinine levels in smokers 
with schizophrenia and schizoafective disorder is not a metabolic 
efect. Schizophr Res 2005; 79: 323–35.
6 Szatkowski L, McNeill A. The delivery of smoking cessation 
interventions to primary care patients with mental health problems. 
Addiction 2013; 108: 1487–94.
7 Jochelson K, Majrowski B. Clearing the air: debating smoke­free 
policies in psychiatric units. London: King’s Fund, 2006.
8 Addington J, el­Guebaly N, Addington D, Hodgins D. Readiness to 
stop smoking in schizophrenia. Can J Psychiatry 1997; 42: 49–52.
9 Taylor G, McNeill A, Girling A, Farley A, Lindson­Hawley N, 
Aveyard P. Change in mental health after smoking cessation: 
systematic review and meta­analysis. BMJ 2014; 348: g1151.
10 Brown S, Kim M, Mitchell C, Inskip H. Twenty­ive year mortality 
of a community cohort with schizophrenia. Br J Psychiatry 2010; 
196: 116–21.
11 National Institute for Health and Care Excellence. Smoking: acute, 
maternity and mental health services. London: National Institute 
for Health and Care Excellence, 2013. https://www.nice.org.uk/
guidance/ph48 (accessed Feb 22, 2019).
12 Banham L, Gilbody SM. Smoking cessation in severe mental 
illness: what works? Addiction 2010; 105: 1176–89.
13 McNally L, Ratschen E. The delivery of stop smoking support to 
people with mental health conditions: a survey of NHS stop 
smoking services. BMC Health Serv Res 2010; 10: 179.
14 Cook BL, Wayne GF, Kafali EN, Liu Z, Shu C, Flores M. Trends in 
smoking among adults with mental illness and association between 
mental health treatment and smoking cessation. JAMA 2014; 
311: 172–82.
15 Bradshaw T, Davies E, Stronach M, Richardson K, Hermann L. 
Helping people with serious mental illness to cut down or stop 
smoking. Mental Health Practice 2014; 17: 14–20.
16 Peckham E, Man M, Mitchell N, et al. Smoking cessation intervention 
for severe mental ill health trial (SCIMITAR): a pilot randomised 
control trial of the clinical efectiveness and cost­efectiveness of a 
bespoke smoking cessation service. Health Technol Assess 2015; 
19: 1–148.
17 Gilbody S, Peckham E, Man MS, et al. Bespoke smoking 
cessation for people with severe mental ill health (SCIMITAR): 
a pilot randomised controlled trial. Lancet Psychiatry 2015; 
2: 395–402.
18 Roland M, Torgerson DJ. Understanding controlled trials: what are 
pragmatic trials? BMJ 1998; 316: 285.
19 Peckham E, Arundel C, Bailey D, et al. Smoking cessation 
intervention for severe mental ill health trial (SCIMITAR+): 
study protocol for a randomised controlled trial. Trials 2017; 18: 44.
20 BMA and NHS Employers. Revisions to the GMS contract, 2008/9. 
Delivering investment in general practice. London: British Medical 
Association, 2008. https://www.nhsemployers.org/your­workforce/
primary­care­contacts/general­medical­services/gms­contract­
changes/contract­changes­2006­2012/contract­changes­2008­09 
(accessed March 26, 2019). 
21 Heatherton TF, Kozlowski LT, Frecker RC, Fagerström K. 
The Fagerström test for nicotine dependence: a revision of the 
Fagerstrom Tolerance Questionnaire. Br J Addict 1991; 86: 1119–27.
22 Crittenden KS, Manfredi C, Lacey L, Warnecke R, Parsons J. 
Measuring readiness and motivation to quit smoking among 
women in public health clinics. Addict Behav 1994; 19: 497–507.
23 Gilbody S, Richards D, Barkham M. Diagnosing depression in 
primary care using self­completed instruments: a UK validation of 
the PHQ­9 and CORE­OM. Br J Gen Pract 2007; 57: 650–52.
24 Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for 
assessing generalized anxiety disorder: the GAD­7. Arch Intern Med 
2006; 166: 1092–97.
25 EuroQol Group. EuroQOL—a new facility for the measurement of 
health related quality of life. Health Policy 1990; 16: 199–208.
26 Ware JE, Kosinski MA, Dewey JE. How to score version 2 of the 
SF­36 health survey. Lincoln, RI: QualityMetric Incorporated, 2000.
27 McEwen A, Hajek P, McRobbie H, West R. Manual of smoking 
cessation: a guide for counsellors and practitioners. London: 
Blackwell Publishing Ltd, 2006.
28 Wang D, Connock M, Barton P, Fry­Smith A, Aveyard P, Moore D. 
‘Cut down to quit’ with nicotine replacement therapies in smoking 
cessation: a systematic review of efectiveness and economic 
analysis. Health Technol Assess 2008; 12: 1–135.
29 Joint Formulary Committee. British National Formulary (BNF). 
London: BMJ Group and Pharmaceutical Press, 2015.
30 West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking 
cessation trials: proposal for a common standard. Addiction 2005; 
100: 299–303.
31 White IR, Royston P, Wood AM. Multiple imputation using chained 
equations: issues and guidance for practice. Stat Med 2011; 30: 377–99.
Articles
390 www.thelancet.com/psychiatry   Vol 6   May 2019
32 Stead LF, Koilpillai P, Fanshawe TR, Lancaster T. 
Combined pharmacotherapy and behavioural interventions for 
smoking cessation. Cochrane Database Syts Rev 2016; 3: CD008286.
33 Wu Q, Gilbody S, Peckham E, Brabyn S, Parrott S. Varenicline for 
smoking cessation and reduction in people with severe mental 
illnesses: systematic review and meta­analysis. Addiction 2016; 
111: 1554–67.
34 Gunnell D, Irvine D, Wise L, Davies C, Martin RM. Varenicline and 
suicidal behaviour: a cohort study based on data from the General 
Practice Research Database. BMJ 2009; 339: b3805.
35 Peckham E, Brabyn S, Cook L, Tew G, Gilbody S. Smoking cessation 
in severe mental ill health: what works? An updated systematic 
review and meta­analysis. BMC Psychiatry 2017; 17: 252.
36 West R, May S, West M, Croghan E, McEwen A. Performance of 
English stop smoking services in irst 10 years: analysis of service 
monitoring data. BMJ 2013; 347: f4921.
37 Cohen A, Hove M. Physical health of the severe and enduring 
mentally ill. London: Sainsbury Centre for Mental Health, 2001.
38 Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety 
and eicacy of varenicline, bupropion, and nicotine patch in 
smokers with and without psychiatric disorders (EAGLES): 
a double­blind, randomised, placebo­controlled clinical trial. 
Lancet 2016; 387: 2507–20.
39 Prochaska JJ, Hall SE, Delucchi K, Hall SM. Eicacy of initiating 
tobacco dependence treatment in inpatient psychiatry: 
a randomized controlled trial. Am J Public Health 2014; 
104: 1557–65.
40 Stockings EA, Bowman JA, Baker AL, et al. Impact of a 
postdischarge smoking cessation intervention for smokers admitted 
to an inpatient psychiatric facility: a randomized controlled trial. 
Nicotine Tob Res 2014; 16: 1417–28.
41 Ashton M, Rigby A, Galletly C. Evaluation of a community­based 
smoking cessation programme for people with severe mental 
illness. Tob Control 2015; 24: 275–80.
42 Parker C, McNeill A, Ratschen E. Tailored tobacco dependence 
support for mental health patients: a model for inpatient and 
community services. Addiction 2012; 107: 18–25.
43 McKee M, Capewell S. Evidence about electronic cigarettes: 
a foundation built on rock or sand? BMJ 2015; 351: h4863.
44 McNeill A, Brose LS, Calder R, Bauld L, Robson D. Evidence review 
of e­cigarettes and heated tobacco products 2018: a report 
commissioned by Public Health England. London: Public Health 
England, 2018.
45 Campion J, Shiers D, Britton J, Gilbody S, Bradshaw T. 
Primary care guidance on smoking and mental disorders—update 
2014. London: Royal College of General Practitioners and Royal 
College of Psychiatrists, 2014.
